Rivera M, McGuffin P. The successful search for genetic loci associated with depression. Genome Med 2015; 7: 92.
Lam RW, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Can J Psychiatry 2004; 49 (3 Suppl 1): 17S–26S.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40.
Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–241.
Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552–1562.
Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73: 679–682.
Gvozdic K, Brandl EJ, Taylor DL, Muller DJ. Genetics and personalized medicine in antidepressant treatment. Curr Pharm Des 2012; 18: 5853–5878.
Dell'osso B, Camuri G, Dobrea C, Buoli M, Serati M, Altamura AC. Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups. Clin Pract Epidemiol Ment Health 2012; 8: 120–125.
Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009; 65: 785–791.
Atake K, Yoshimura R, Hori H, Katsuki A, Nakamura J. Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder. Neuropsychiatr Dis Treat 2015; 11: 967–974.
Houston JP, Kohler J, Ostbye KM, Heinloth A, Perlis RH. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder. Psychiatry Res 2011; 189: 475–477.
Houston JP, Zou W, Aris V, Fijal B, Chen P, Heinloth AN et al. Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder. Psychiatry Res 2012; 200: 63–65.
Maciukiewicz M, Marshe VS, Tiwari AK, Fonseka TM, Freeman N, Rotzinger S et al. Genetic variation in IL-1beta, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder. Pharmacogenomics 2015; 16: 1919–1929.
Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67: 1110–1113.
Perlis RH, Fijal B, Dharia S, Houston JP. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J 2013; 13: 280–285.
Garcia-Gonzalez J, Tansey KE, Hauser J, Henigsberg N, Maier W, Mors O et al. Pharmacogenetics of antidepressant response: a polygenic approach. Prog Neuropsychopharmacol Biol Psychiatry 2017; 75: 128–134.
Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009; 118: 1–8.
Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol 2009; 29: 372–377.
Tiwari AK, Zai CC, Sajeev G, Arenovich T, Muller DJ, Kennedy JL. Analysis of 34 candidate genes in bupropion and placebo remission. Int J Neuropsychopharmacol 2013; 16: 771–781.
Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med 2015; 21: 285–294.
H. Lundbeck A/S. A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu aa21004, in Acute Treatment of Major Depressive Disorder. ClinicalTrials.gov. National Library of Medicine (US): Bethesda, MD, 2000.
H. Lundbeck A/S. A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Dose-Finding Study of Lu aa24530 in Major Depressive Disorder. ClinicalTrials.gov. National Library of Medicine (US): Bethesda, MD, 2000.
H. Lundbeck A/S. A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Evaluating the Efficacy and Safety of Lu AA21004 (15 and 20 mg/day) in the Acute Treatment of Adult Patients with Major Depressive Disorder. ClinicalTrials.gov. National Library of Medicine (US): Bethesda, MD, 2000.
Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C et al. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry 2016; 16: 105.
Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012; 40: D930–934.
Dong S, Walker MF, Carriero NJ, DiCola M, Willsey AJ, Ye AY et al. De novo insertions and deletions of predominantly paternal origin are associated with autism spectrum disorder. Cell Rep 2014; 9: 16–23.
Shen E, Shulha H, Weng Z, Akbarian S. Regulation of histone H3K4 methylation in brain development and disease. Philos Trans R Soc Lond B Biol Sci 2014; 369: 20130514.
Wedzony K, Chocyk A, Mackowiak M. Potential roles of NCAM/PSA-NCAM proteins in depression and the mechanism of action of antidepressant drugs. Pharmacol Rep 2013; 65: 1471–1478.
Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 2009; 14: 764–773, 739.
Xu C, Aragam N, Li X, Villla EC, Wang L, Briones D et al. BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies. PLoS ONE 2013; 8: e51674.
Eicher JD, Powers NR, Miller LL, Akshoomoff N, Amaral DG, Bloss CS et al. Genome-wide association study of shared components of reading disability and language impairment. Genes Brain Behav 2013; 12: 792–801.
Hotaling JM, Waggott DR, Goldberg J, Jarvik G, Paterson AD, Cleary PA et al. Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort. J Urol 2012; 188: 514–520.
Ostensson M, Monten C, Bacelis J, Gudjonsdottir AH, Adamovic S, Ek J et al. A possible mechanism behind autoimmune disorders discovered by genome-wide linkage and association analysis in celiac disease. PLoS ONE 2013; 8: e70174.
Trabzuni D, Ryten M, Walker R, Smith C, Imran S, Ramasamy A et al. Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem 2011; 119: 275–282.
Suzuki H, Kawai J, Taga C, Yaoi T, Hara A, Hirose K et al. Stac, a novel neuron-specific protein with cysteine-rich and SH3 domains. Biochem Biophys Res Commun 1996; 229: 902–909.
Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 2012; 489: 391–399.
Schneider KK, Schote AB, Meyer J, Markett S, Reuter M, Frings C. Individual response speed is modulated by variants of the gene encoding the alpha 4 sub-unit of the nicotinic acetylcholine receptor (CHRNA4). Behav Brain Res 2015; 284: 11–18.
Chaijale NN, Snyder K, Arner J, Curtis AL, Valentino RJ. Repeated social stress increases reward salience and impairs encoding of prediction by rat locus coeruleus neurons. Neuropsychopharmacology 2015; 40: 513–523.
Dayan CM, Panicker V. Novel insights into thyroid hormones from the study of common genetic variation. Nat Rev Endocrinol 2009; 5: 211–218.
Wu EL, Chien IC, Lin CH, Chou YJ, Chou P. Increased risk of hypothyroidism and hyperthyroidism in patients with major depressive disorder: a population-based study. J Psychosom Res 2013; 74: 233–237.
Ittermann T, Volzke H, Baumeister SE, Appel K, Grabe HJ. Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol 2015; 50: 1417–1425.
Pecina M, Martinez-Jauand M, Hodgkinson C, Stohler CS, Goldman D, Zubieta JK. FAAH selectively influences placebo effects. Mol Psychiatry 2014; 19: 385–391.
Pecina M, Martinez-Jauand M, Love T, Heffernan J, Montoya P, Hodgkinson C et al. Valence-specific effects of BDNF Val66Met polymorphism on dopaminergic stress and reward processing in humans. J Neurosci 2014; 34: 5874–5881.
Bhathena A, Wang Y, Kraft JB, Idler KB, Abel SJ, Holley-Shanks RR et al. Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response. Transl Psychiatry 2013; 3: e245.
Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci 2008; 28: 13066–13074.
Brandl EJ, Tiwari AK, Zai CC, Nurmi EL, Chowdhury NI, Arenovich T et al. Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. Pharmacogenomics J 2016; 16: 352–356.